73
Participants
Start Date
October 30, 2017
Primary Completion Date
December 31, 2022
Study Completion Date
July 19, 2023
Dordaviprone (ONC201)
Dordaviprone (ONC201) is a central nervous system (CNS)-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.
New York University School of Medicine, New York
Columbia University, New York
Hospital of the University of Pennsylvania, Philadelphia
Levine Cancer Institute, Charlotte
University of Michigan, Ann Arbor
University of Minnesota, Minneapolis
MD Anderson Cancer Center, Houston
Stanford Cancer Center, Stanford
University of California, San Francisco, San Francisco
Lead Sponsor
Collaborators (1)
Oncoceutics, Inc.
INDUSTRY
Jazz Pharmaceuticals
INDUSTRY